Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2014

View Archived Issues

Full year report - 2013 was a successful year for Lundbeck

Technetium Tc 99m trofolastat accurately detects cancer in the prostate gland

Takeda Pharmaceutical advances key programs in third quarter of fiscal 2013

ARADES and ARAFOR trial data reported for ODM-201 in prostate cancer

Protalex reports data from phase Ib trial of PRTX-100 in active rheumatoid arthritis

arGEN-X begins phase Ib study of ARGX-111

GlaxoSmithKline reports discovery of selective androgen receptor modulators

First-in-human clinical evaluation of a sustained-release exenatide for the treatment of diabetes

Ganymed Pharmaceuticals begins phase I/II trial of IMAB-027 in advanced ovarian cancer

Merck & Co. discloses new HIV prodrugs

Regeneron Pharmaceuticals and Bayer HealthCare report 2-year data from VISTA-DME trial

New targeted immunotherapy compounds designed by Shanghai Birdie Biotech

EMA's Committee for Orphan Medicinal Products issues positive opinion on Arikace

Biogen Idec patent divulges novel S1P modulating agents

Merck & Co. reports development of DPP IV inhibitors for diabetes

Sarepta Therapeutics reports safety data from phase I study of AVI-7288

Study of Repros' Androxal shows sustained effect in men with secondary hypogonadism

Aduro BioTech begins phase IIb ECLIPSE trial in patients with pancreatic cancer

Audion Therapeutics and Lilly to develop hearing loss treatments

Results from preliminary safety study evaluating trebananib plus abiraterone in patients with CRPC

Gilead submits NDA for fixed-dose combination tablet for HCV infection

Lipocine begins dosing in pivotal SOAR study

Oramed submits phase IIa protocol to FDA for oral insulin capsule

Scancell's SCIB-1 receives FDA orphan drug status for metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...